Comparable stake leader
Roivant Sciences Ltd.
SEC ownership of Immunovant, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001764013.
Disclosed value leader
Roivant Sciences Ltd.
Comparable rows
50/50
Latest evidence
28 May 2026
- Public ticker
- IMVT on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Roivant Sciences Ltd.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Roivant Sciences Ltd.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
28 May 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001764013
- Issuer location
- Durham, NC
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Immunovant, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Roivant Sciences Ltd.
Disclosed value leader
Roivant Sciences Ltd.
Comparable rows
50/50
Latest evidence
28 May 2026
13D/G
3/4/5
13F
Lead comparable stake: 56%
13D/G row: Roivant Sciences Ltd.
Showing 1-8 of 50 holder rows.
Quick read
Roivant Sciences Ltd. leads the comparable SEC ownership view at 56%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Roivant Sciences Ltd.'s linked filing trail.
Comparable ownership
Top 5
Roivant Sciences Ltd.
56%
FMR LLC
8.4%
Deep Track Capital, LP
5.6%
Andrew J. Fromkin
0.04%
BlackRock, Inc.
3.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Roivant Sciences Ltd. |
13D/G
3/4/5
Director, 10%+ Owner
|
56%
|
$2,812,776,314
113,327,007 shares
|
+$413,666,650 | 12 Dec 2025 |
| FMR LLC |
13F
13D/G
Company
|
8.4%
from 13D/G
|
$420,985,547
16,947,888 shares
|
— | 31 Mar 2026 |
| Deep Track Capital, LP |
13F
13D/G
Company
|
5.6%
from 13D/G
|
$286,329,960
11,526,971 shares
|
— | 31 Mar 2026 |
| Andrew J. Fromkin |
3/4/5
Director
|
0.04%
|
$2,496,259
74,382 shares
|
-$7,955,300 | 28 May 2026 |
| BlackRock, Inc. |
13F
Company
|
3.2%
|
$163,310,512
6,574,497 shares
|
— | 31 Mar 2026 |
| BAKER BROS. ADVISORS LP |
13F
Company
|
2.7%
|
$135,573,764
5,457,881 shares
|
— | 31 Mar 2026 |
| STATE STREET CORP |
13F
Company
|
2.2%
|
$112,722,156
4,537,929 shares
|
— | 31 Mar 2026 |
| TCG Crossover Management, LLC |
13F
Company
|
2.2%
|
$110,736,422
4,457,988 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$334,952,605.
Buys
$349,999,986
Insiders: 1
Sells
$15,047,381
Insiders: 10
Net
+$334,952,605
Shares: +16,189,340
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 16,666,666
Shares: 477,326
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 377,273 | $0 | $12,719,802 | -$12,719,802 |
| 3-6 | 0 | 23,524 | $0 | $588,252 | -$588,252 |
| 6-9 | 16,666,666 | 68,660 | $349,999,986 | $1,598,942 | +$348,401,044 |
| 9-12 | 0 | 7,869 | $0 | $140,384 | -$140,384 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-19 of 19 reporting-owner rows connected to Immunovant, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
19
Largest Forms 3/4/5 holder
Roivant Sciences Ltd.
Net 12M change
+$334,952,607
Latest report
26 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Roivant Sciences Ltd. | Director, 10%+ Owner | $2,379,657,147 | +$349,999,986 | +17% | Filing P/S | 12 Dec 2025 |
| Frank Torti | Director | $25,068,718 | Median | 07 Apr 2026 | ||
| Peter Salzmann | Chief Executive Officer, Director | $17,543,264 | Filing P/S | 16 Apr 2025 | ||
| Julia G. Butchko | Chief Development Officer | $14,251,795 | Filing P/S | 21 Aug 2024 | ||
| Tiago Girao | Chief Financial Officer | $9,522,542 | -$1,147,611 | -11% | Filing P/S | 26 Jun 2026 |
| Melanie Gloria | Chief Operating Officer | $8,740,107 | -$1,384,665 | -14% | Filing P/S | 26 Jun 2026 |
| Jay S. Stout | Chief Technology Officer | $8,243,013 | -$2,099,725 | -20% | Filing P/S | 26 Jun 2026 |
| Mark S. Levine | Chief Legal Officer | $8,124,353 | Filing P/S | 20 Nov 2024 | ||
| William L. Macias | Chief Medical Officer | $7,454,384 | Filing P/S | 19 Feb 2025 | ||
| Christopher van Tuyl | Chief Legal Officer | $7,036,059 | -$1,267,132 | -15% | Filing P/S | 26 Jun 2026 |
| Eric Venker | Chief Executive Officer, Director | $6,254,909 | -$342,854 | -5.2% | Median | 07 Apr 2026 |
| Eva Renee Barnett | Chief Financial Officer | $5,907,965 | Filing P/S | 16 Apr 2025 | ||
| Atul Pande | Director | $4,933,745 | -$300,045 | -5.7% | Mixed | 26 Jun 2026 |
| Michael Geffner | Chief Medical Officer | $4,147,740 | -$133,403 | -3.1% | Filing P/S | 22 Oct 2025 |
| Douglas J. Hughes | Director | $3,344,713 | -$348,665 | -9.4% | Median | 07 Apr 2026 |
| George Migausky V | Director | $2,739,530 | Mixed | 01 Apr 2025 | ||
| Andrew J. Fromkin | Director | $2,496,259 | -$7,955,300 | -76% | Filing P/S | 28 May 2026 |
| Robert Graham Susman | Director | $988,824 | -$67,979 | -6.4% | Filing P/S | 01 May 2026 |
| Jake Bauer | Director | $966,157 | Median | 07 Apr 2026 |
Recent insider transactions for Immunovant, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Melanie Gloria | IMVT | Common Stock | Sale | -7.32% | $678,604 | $38.31 | -17,714 | 224,393 | 26 Jun 2026 | Direct |
| Jay S. Stout | IMVT | Common Stock | Sale | -15.9% | $1,532,309 | $38.31 | -40,000 | 211,685 | 26 Jun 2026 | Direct |
| Christopher van Tuyl | IMVT | Common Stock | Sale | -8.98% | $682,887 | $38.31 | -17,824 | 180,597 | 26 Jun 2026 | Direct |
| Christopher van Tuyl | IMVT | Common Stock | Options Exercise | 9.87% | 17,824 | 198,421 | 26 Jun 2026 | Direct | ||
| Christopher van Tuyl | IMVT | Stock Option (right to buy) | Options Exercise | -24.9% | -17,824 | 53,707 | 26 Jun 2026 | Direct | ||
| Tiago Girao | IMVT | Common Stock | Sale | -3.88% | $384,600 | $38.46 | -10,000 | 247,596 | 26 Jun 2026 | Direct |
| Tiago Girao | IMVT | Common Stock | Options Exercise | 4.04% | 10,000 | 257,596 | 26 Jun 2026 | Direct | ||
| Tiago Girao | IMVT | Stock Option (right to buy) | Options Exercise | -3.41% | -10,000 | 283,505 | 26 Jun 2026 | Direct | ||
| Atul Pande | IMVT | Common Stock | Sale | -1.27% | $57,015 | $38.01 | -1,500 | 116,731 | 26 Jun 2026 | Direct |
| Atul Pande | IMVT | Common Stock | Options Exercise | 1.29% | 1,500 | 118,231 | 26 Jun 2026 | Direct | ||
| Atul Pande | IMVT | Stock Option (right to buy) | Options Exercise | -2.15% | -1,500 | 68,181 | 26 Jun 2026 | Direct | ||
| Christopher van Tuyl | IMVT | Common Stock | Sale | -1.44% | $93,217 | $35.39 | -2,634 | 180,597 | 18 Jun 2026 | Direct |
| Atul Pande | IMVT | Common Stock | Sale | -1.27% | $51,030 | $34.02 | -1,500 | 116,731 | 15 Jun 2026 | Direct |
| Atul Pande | IMVT | Common Stock | Options Exercise | 1.29% | 1,500 | 118,231 | 15 Jun 2026 | Direct | ||
| Atul Pande | IMVT | Stock Option (right to buy) | Options Exercise | -2.11% | -1,500 | 69,681 | 15 Jun 2026 | Direct | ||
| Andrew J. Fromkin | IMVT | Common Stock | Sale | -74.9% | $7,438,111 | $33.51 | -221,951 | 74,382 | 28 May 2026 | Direct |
| Andrew J. Fromkin | IMVT | Common Stock | Options Exercise | 197.1% | 196,601 | 296,333 | 28 May 2026 | Direct | ||
| Andrew J. Fromkin | IMVT | Stock Option (right to buy) | Options Exercise | -100% | -196,601 | 0 | 28 May 2026 | Direct | ||
| Melanie Gloria | IMVT | Common Stock | Sale | -1.27% | $101,072 | $32.45 | -3,115 | 242,107 | 20 May 2026 | Direct |
| Atul Pande | IMVT | Common Stock | Sale | -4.89% | $192,000 | $32.00 | -6,000 | 116,731 | 20 May 2026 | Direct |
| Atul Pande | IMVT | Common Stock | Options Exercise | 5.14% | 6,000 | 122,731 | 20 May 2026 | Direct | ||
| Atul Pande | IMVT | Stock Option (right to buy) | Options Exercise | -2.17% | -6,000 | 270,252 | 20 May 2026 | Direct | ||
| Robert Graham Susman | IMVT | Common Stock | Sale | -6.43% | $67,979 | $27.17 | -2,502 | 36,394 | 01 May 2026 | Direct |
| Tiago Girao | IMVT | Common Stock | Sale | -9.42% | $763,011 | $29.62 | -25,760 | 247,596 | 23 Apr 2026 | Direct |
| Jay S. Stout | IMVT | Common Stock | Sale | -1.08% | $81,573 | $29.62 | -2,754 | 251,685 | 23 Apr 2026 | Direct |
| Christopher van Tuyl | IMVT | Common Stock | Sale | -2.74% | $128,247 | $24.83 | -5,165 | 183,231 | 08 Apr 2026 | Direct |
| Melanie Gloria | IMVT | Common Stock | Sale | -3.43% | $216,567 | $24.83 | -8,722 | 245,222 | 08 Apr 2026 | Direct |
| Jay S. Stout | IMVT | Common Stock | Sale | -3.83% | $251,578 | $24.83 | -10,132 | 254,439 | 08 Apr 2026 | Direct |
| Frank Torti | IMVT | Common Stock | Award | 20.9% | 174,189 | 1,009,228 | 07 Apr 2026 | Direct | ||
| Frank Torti | IMVT | Stock Option (right to buy) | Award | 88,325 | 88,325 | 07 Apr 2026 | Direct | |||
| Andrew J. Fromkin | IMVT | Common Stock | Award | 16.2% | 13,880 | 99,732 | 07 Apr 2026 | Direct | ||
| Andrew J. Fromkin | IMVT | Stock Option (right to buy) | Award | 7,061 | 7,061 | 07 Apr 2026 | Direct | |||
| Douglas J. Hughes | IMVT | Common Stock | Award | 11.5% | 13,880 | 134,653 | 07 Apr 2026 | Direct | ||
| Douglas J. Hughes | IMVT | Stock Option (right to buy) | Award | 7,061 | 7,061 | 07 Apr 2026 | Direct | |||
| Atul Pande | IMVT | Common Stock | Award | 13.5% | 13,880 | 116,731 | 07 Apr 2026 | Direct | ||
| Atul Pande | IMVT | Stock Option (right to buy) | Award | 7,061 | 7,061 | 07 Apr 2026 | Direct | |||
| Jake Bauer | IMVT | Common Stock | Award | 55.5% | 13,880 | 38,896 | 07 Apr 2026 | Direct | ||
| Jake Bauer | IMVT | Stock Option (right to buy) | Award | 7,061 | 7,061 | 07 Apr 2026 | Direct | |||
| Robert Graham Susman | IMVT | Common Stock | Award | 55.5% | 13,880 | 38,896 | 07 Apr 2026 | Direct | ||
| Robert Graham Susman | IMVT | Stock Option (right to buy) | Award | 7,061 | 7,061 | 07 Apr 2026 | Direct | |||
| Melanie Gloria | IMVT | Common Stock | Award | 49.1% | 83,671 | 253,944 | 07 Apr 2026 | Direct | ||
| Melanie Gloria | IMVT | Stock Option (right to buy) | Award | 121,063 | 121,063 | 07 Apr 2026 | Direct | |||
| Jay S. Stout | IMVT | Common Stock | Award | 33.9% | 66,937 | 264,571 | 07 Apr 2026 | Direct | ||
| Jay S. Stout | IMVT | Stock Option (right to buy) | Award | 96,851 | 96,851 | 07 Apr 2026 | Direct | |||
| Christopher van Tuyl | IMVT | Common Stock | Award | 28.1% | 41,343 | 188,396 | 07 Apr 2026 | Direct | ||
| Christopher van Tuyl | IMVT | Stock Option (right to buy) | Award | 59,820 | 59,820 | 07 Apr 2026 | Direct | |||
| Eric Venker | IMVT | Common Stock | Award | 1187.3% | 232,252 | 251,813 | 07 Apr 2026 | Direct | ||
| Eric Venker | IMVT | Stock Option (right to buy) | Award | 336,043 | 336,043 | 07 Apr 2026 | Direct | |||
| Tiago Girao | IMVT | Common Stock | Award | 31.2% | 64,968 | 273,356 | 07 Apr 2026 | Direct | ||
| Tiago Girao | IMVT | Stock Option (right to buy) | Award | 94,002 | 94,002 | 07 Apr 2026 | Direct |
* marks a reported price that did not pass the local price check.